Rufinamide — Membership Pricing

Other medications in Neurological

• Selegiline
• Siponimod
• Sumatriptan
• Teriflunomide
• Tiagabine
• Trihexyphenidyl
• Ubrogepant
• Valproate IV

About Rufinamide

Rufinamide is an important anticonvulsant medication primarily used to manage seizures associated with Lennox-Gastaut Syndrome, a severe form of epilepsy. For individuals and families facing the challenge of managing this condition, understanding treatment options and associated costs is vital. TheDrugClub is dedicated to helping members access necessary medications like rufinamide more affordably, making healthcare more manageable.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Rufinamide is approved for (FDA label)

Rufinamide is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. Rufinamide is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults (1)

Source: Read the full FDA label on DailyMed. Label effective date: September 4, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rufinamide (FDA label)

Oral Suspension: 40 mg/mL. Oral suspension: 40 mg/mL (3)

Source: FDA prescribing information (DailyMed). Set ID: 1a0b80de-754d-4e60-b5a9-b6daa323bf58. SPL document ID: 5aa99d72-bc7f-1ea4-e063-6294a90a119e. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rufinamide (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Behavior and Ideation [see Warnings and Precautions (5.1) ] Central Nervous System Reactions [see Warnings and Precautions (5.2) ] QT Shortening [see Warnings and Precautions (5.3) ] Multi-Organ Hypersensitivity/ Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) [see Warnings and Precautions (5.4) ] Leukopenia [see Warnings and Precautions (5.7) ] Most common adverse reactions (≥10% and greater than placebo) were headache, dizziness, fatigue, somnolence, and nausea (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 1a0b80de-754d-4e60-b5a9-b6daa323bf58. SPL document ID: 5aa99d72-bc7f-1ea4-e063-6294a90a119e. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rufinamide (FDA label)

Rufinamide is contraindicated in patients with Familial Short QT syndrome [see Warnings and Precautions (5.3) ] . Rufinamide is contraindicated in patients with Familial Short QT syndrome (4)

Source: FDA prescribing information (DailyMed). Set ID: 1a0b80de-754d-4e60-b5a9-b6daa323bf58. SPL document ID: 5aa99d72-bc7f-1ea4-e063-6294a90a119e. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rufinamide (FDA label)

Monitor patients for new or worsening depression, suicidal thoughts/behavior, and unusual changes in mood or behavior (5.1) Central nervous system reactions can occur (5.2) Use caution when administering rufinamide with other drugs that shorten the QT interval (5.3) Discontinue rufinamide if multi-organ hypersensitivity reaction occurs (5.4) Withdraw rufinamide gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus (5.5) 5.1 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including rufinamide, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Source: FDA prescribing information (DailyMed). Set ID: 1a0b80de-754d-4e60-b5a9-b6daa323bf58. SPL document ID: 5aa99d72-bc7f-1ea4-e063-6294a90a119e. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rufinamide (FDA label)

Patients on valproate should begin at a rufinamide dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults) (7.2) Hormonal contraceptives may be less effective with rufinamide; use additional non-hormonal forms of contraception (7.3) 7.1 Effects of Rufinamide on other AEDs Population pharmacokinetic analysis of average concentration at steady state of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, and valproate showed that typical rufinamide C avss levels had little effect on the pharmacokinetics of other AEDs. Any effects, when they occur, have been more marked in the pediatric population. Table 6 summarizes the drug-drug interactions of rufinamide with other AEDs. Table 6: Summary of Drug-Drug Interactions of Rufinamide with Other Antiepileptic Drugs AED Co-administered Influence of Rufinamide on AED concentration Predictions are based on rufinamide concentrations at the maximum recommended dose of rufinamide.

Source: FDA prescribing information (DailyMed). Set ID: 1a0b80de-754d-4e60-b5a9-b6daa323bf58. SPL document ID: 5aa99d72-bc7f-1ea4-e063-6294a90a119e. Label effective date: September 4, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.